New

CEFOTETAN POWDER FOR INJECTION

New

CEFOTETAN POWDER FOR INJECTION

  • Injectable

Overview

NDC #
Strength
Product/Case Size
NDC #
00121-0976-10
Strength
1 g/10 mL
Product/Case Size
10 vials/carton
NDC #
00121-0977-10
Strength
2 g/20 mL
Product/Case Size
10 vials/carton
00121-0976-10
1 g/10 mL
10 vials/carton
00121-0977-10
2 g/20 mL
10 vials/carton

Wholesale Ordering

NDC #
Cardinal
Cencora
McKesson
Morris Dickson
NDC #
00121-0976-10
Cardinal
5914569
Cencora
10290478
McKesson
2932531
Morris Dickson
367714
NDC #
00121-0977-10
Cardinal
5914577
Cencora
10290467
McKesson
2932564
Morris Dickson
367722
00121-0976-10
5914569
10290478
2932531
367714
00121-0977-10
5914577
10290467
2932564
367722

Key Info

Compared to: Cefotan®

Free From:

N/A

Rx or OTC:

Rx

Flavor:

N/A

Storage & Handling:

Controlled Room between 20° and 25°C (68° – 77°F); protect from light

Indications:

Indicated for the therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms:

  • Urinary Tract Infections caused by E. coli, Klebsiella spp (including K. pneumoniae), Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, and Morganella morganii.
  • Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (methicillin susceptible), Haemophilus influenzae, Klebsiella species (including K. pneumoniae), E. coli, Proteus mirabilis, and Serratia marcescens.*
  • Skin and Skin Structure Infections due to Staphylococcus aureus (methicillin-susceptible), Staphylococcus epidermidis (methicillin susceptible), Streptococcus pyogenes, Streptococcus species, Escherichia coli, Klebsiella pneumoniae, Peptococcus niger*, Peptostreptococcus species.
  • Gynecologic Infections caused by Staphylococcus aureus (methicillin susceptible), Staphylococcus epidermidis (methicillin susceptible, Streptococcus species, Streptococcus agalactiae, E. coli, Proteus mirabilis, Neisseria gonorrhoeae, Bacteroides fragilis, Prevotella melaninogenica, Bacteroides vulgatus, Fusobacterium species*, and gram-positive anaerobic cocci (including Peptococcus niger and Peptostreptococcus species).

    Cefotetan, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of pelvic inflammatory disease, and C. trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added.
  • Intra-abdominal Infections caused by E. coli, Klebsiella species (including K. pneumoniae), Streptococcus species, Bacteroides fragilis, Prevotella melaninogenica, Bacteroides vulgatus and Clostridium species (other than Clostridium difficile*.
  • Bone and Joint Infections caused by Staphylococcus aureus (methicillin susceptible)*.
*Efficacy for this organism in this organ system was studied in fewer than ten infections in clinical studies. Please see full Prescribing Information for more information.